Ronald Blue Trust, Inc. Neurocrine Biosciences Inc Transaction History
Ronald Blue Trust, Inc.
- $7.7 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 78 shares of NBIX stock, worth $9,140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78
Previous 609
87.19%
Holding current value
$9,140
Previous $83,000
87.95%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NBIX
# of Institutions
643Shares Held
94.7MCall Options Held
615KPut Options Held
570K-
Black Rock Inc. New York, NY14.2MShares$1.66 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.19 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$603 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$302 Million0.47% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$220 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...